Claims for Patent: 7,309,605

Summary for Patent: 7,309,605

Title:	Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
Abstract:	An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Inventor(s):	Dujon; Bernard (Gif sur Yvette, FR), Choulika; Andre (Paris, FR), Perrin; Arnaud (Paris, FR), Nicolas; Jean-Francois (Noisy le Roi, FR)
Assignee:	Institut Pasteur (Paris, FR) Universite Pierre et Marie Curie (Paris, FR)
Application Number:	10/820,843
Patent Claims:	1. A method for inducing at least one site directed double-stranded break in the DNA of an organism comprising: (a) providing an isolated cell of said organism containing at least one Group I intron encoded endonuclease recognition site at a location in the DNA of the cell, (b) providing said Group I intron encoded endonuclease to said cell by genetically modifying the cell with a nucleic acid comprising said Group I intron encoded endonuclease or by introducing said Group I intron encoded endonuclease protein into the cell such that the Group I intron encoded endonuclease cleaves said Group I intron encoded endonuclease site at the location in the DNA of the cell. 2. The method of claim 1, wherein the site is an I-SceIV site. 3. The method of claim 1, wherein the site is an I-CsmI site. 4. The method of claim 1, wherein the site is an I-PanI site. 5. The method of claim 1, wherein the site is an I-SceII site. 6. The method of claim 1, wherein the site is an I-CeuI site. 7. The method of claim 1, wherein the site is an I-Ppol site. 8. The method of claim 1, wherein the site is an I-SceIII site. 9. The method of claim 1, wherein the site is an I-CreI site. 10. The method of claim 1, wherein the site is an I-TevI site. 11. The method of claim 1, wherein the site is an I-TevII site. 12. The method of claim 1, wherein the site is an I-TevIII site. 13. The method of claim 1, wherein the site is an I-SceI site. 14. The method of claim 1, wherein said method further comprises providing to said cell a plasmid comprising a DNA sequence homologous to the sequence of the chromosome, which allows homologous recombination, and a modified sequence, wherein said Group I intron encoded endonuclease cleaves the Group I intron encoded endonuclease recognition site, whereby said cleavage promotes the insertion of said modified sequence into said DNA of said cell at a specific site by homologous recombination. 15. The method of claim 1, wherein said Group I intron encoded endonuclease cleaves the DNA at a unique location in the genome. 16. The method of claim 1, wherein said Group I intron encoded endonuclease recognition site is located between two DNA direct repeats, wherein said Group I intron encoded endonuclease cleaves the Group I intron encoded endonuclease recognition site, whereby said cleavage promotes the recombination between the two direct repeats leading to the deletion of one repeat and sequences between the repeats. 17. The method of claim 16, wherein said sequences between the repeats comprises a selectable marker.

Details for Patent 7,309,605

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2012-05-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2012-05-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2012-05-05